Arbutus Biopharma Stock Forecast

Stock Price Forecast

The 4 analysts that cover Arbutus Biopharma stock have a consensus rating of "Strong Buy" and an average price target of $5.5, which forecasts a 71.87% increase in the stock price over the next year. The lowest target is $5 and the highest is $7.

Price Target: $5.5 (+71.87%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$5.00	$5.50	$5.00	$7.00
Change	+56.25%	+71.87%	+56.25%	+118.75%

* Price targets were last updated on Mar 28, 2025.

Analyst Ratings

The average analyst rating for Arbutus Biopharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '25	Feb '25	Mar '25	Apr '25	May '25	Jun '25
Strong Buy	3	3	3	3	3	3
Buy	1	1	1	1	1	1
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	4	4	4	4	4	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Keay Nakae Chardan Capital	Chardan Capital	Strong Buy Maintains $5	Strong Buy	Maintains	$5	+56.25%	Mar 28, 2025
Ed Arce HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $5	Strong Buy	Reiterates	$5	+56.25%	Jan 21, 2025
Keay Nakae Chardan Capital	Chardan Capital	Strong Buy Maintains $4.5 → $5	Strong Buy	Maintains	$4.5 → $5	+56.25%	Nov 20, 2024
Ed Arce HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $5	Strong Buy	Reiterates	$5	+56.25%	Nov 18, 2024
Ed Arce HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $5	Strong Buy	Reiterates	$5	+56.25%	Nov 7, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

6.38M

from 6.17M

3.35%

from 6.17M

Revenue Next Year

4.52M

from 6.38M

-29.10%

from 6.38M

EPS This Year

-0.27

from -0.38

EPS Next Year

-0.24

from -0.27

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	6.91M	10.99M	39.02M	18.14M	6.17M	6.38M	4.52M	9.01M
Revenue Growth	15.02%	58.92%	255.11%	-53.51%	-65.98%	3.35%	-29.10%	99.23%
EPS	-1.00	-0.83	-0.46	-0.44	-0.38	-0.27	-0.24	-0.05
EPS Growth	-	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	7	6	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	7.5M	7.5M	9.3M
Avg	6.4M	4.5M	9.0M
Low	4.5M	2.7M	8.7M

Revenue Growth

Revenue Growth	2025	2026	2027
High	20.8%	16.9%	105.1%
Avg	3.4%	-29.1%	99.2%
Low	-26.9%	-57.0%	91.4%

EPS Forecast

EPS	2025	2026	2027
High	-0.21	-0.19	-0.05
Avg	-0.27	-0.24	-0.05
Low	-0.31	-0.28	-0.05

EPS Growth

EPS Growth	2025	2026	2027
High	-	-	-
Avg	-	-	-
Low	-	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.